What Are Peptides? The Science, Therapeutic Applications & Future of Signaling Molecules

Peptides are short chains of amino acids: the FDA's legal cut-off is 40 amino acids, above which a chain counts as a protein, and more than 80 peptide drugs have been approved worldwide, among them Semaglutide in Wegovy and Ozempic. Most peptides in the body carry signals, and most peptide drugs work the same way: they bind a receptor on a cell and change what that cell does.

The word now covers a second market too: unapproved "research peptides" such as BPC-157, sold online under a research-use-only label, with no approved dose and often no human trial. The systematic review "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review" (Vasireddi et al., 2025) screened 544 records on that compound and kept 35 animal or cell studies and a single human report. For a vial from that market, the first question is what it contains, and 13,190 third-party lab certificates answering it for specific vials are published in the peptide lab tests database on this site (verified September 2026).

The short version

• A peptide is a short chain of amino acids, and US regulators treat a chain of 40 amino acids or fewer as a peptide and anything longer as a protein.

• More than 80 peptide drugs are approved worldwide, each for a named condition after human trials, and each comes with a label that states its dose and its side effects.

• Most research peptides sold online rest on animal studies, and the only human report a 2025 review of BPC-157's orthopedic use found was a retrospective series of 12 people with knee pain.

• A certificate's purity figure does not prove that a vial holds the right molecule or the labeled amount, and 7.24% of the net-content results on this site came in below 95% of the label (verified September 2026).

• As of September 2026, none of the research peptides an FDA advisory panel reviewed in July 2026 has been added to the list of substances US pharmacies may compound, because the panel's votes were recommendations, not approvals.

What is a peptide, and where does a peptide end and a protein begin?

A peptide is a chain of amino acids, the 20 standard building blocks of protein, joined by peptide bonds, and US regulators put its upper limit at 40 amino acids. Under an FDA rule in force since March 23, 2020, a chain of more than 40 is a protein and is regulated as a biologic, which is why insulin, at 51 amino acids in two chains, now counts as a protein. Textbooks draw the boundary in different places, so 40 is a legal convention, not a law of chemistry.

The FDA's final rule "Definition of the Term "Biological Product"" (2020) defines a protein as an amino acid chain with a specific, defined sequence "greater than 40 amino acids in size," and acknowledges in the same document that there may be no clear scientific consensus on a single cut-off. Two names are fixed by their prefixes: a dipeptide has 2 amino acids and a tripeptide has 3. "Oligopeptide" and "polypeptide" have no agreed boundaries.

The four molecules below run from a 10-amino-acid brain hormone to insulin, and the FDA's line falls between the third and the fourth.

Chemists weigh molecules in daltons (Da), a unit roughly equal to the mass of one hydrogen atom. Most therapeutic peptides weigh between 500 and 5,000 Da, according to the 2022 review "Therapeutic peptides: current applications and future directions" (Wang et al., 2022). The same review notes that chemical synthesis of chains under 50 residues (the amino acids once they are linked) is routine, while longer chains are still hard to make at scale.

What do peptides do in the body?

Peptides in the body mostly carry signals: one tissue releases a peptide, and it binds a receptor, a protein on the surface of another cell that recognizes that one molecule, to switch a process on or off. GLP-1, a 37-amino-acid gut hormone, regulates insulin release and appetite this way. Peptide drugs work on the same principle, acting as hormones, growth factors, neurotransmitters (nerve-signal chemicals) or anti-infective agents, according to a 2022 review of the field.

More than 90% of the peptides in active clinical development act on targets outside the cell, because peptides pass through cell membranes poorly, according to that review, which draws the figure from a 2018 analysis by Lau and Dunn. Each peptide fits its receptor closely, so peptide drugs are more selective than many small-molecule drugs, and compared with antibody drugs they provoke fewer immune reactions and cost less to make.

Three signals show the range. Insulin lowers blood sugar. GnRH, a 10-amino-acid hormone made in the hypothalamus, controls the release of reproductive hormones. GLP-1 itself has a very short half-life in the body, which is why every GLP-1 drug is an engineered copy built to last longer.

How many peptide drugs are approved, and what do they treat?

More than 80 peptide drugs have reached the market since insulin, according to a 2021 review in Nature Reviews Drug Discovery, and they treat conditions from diabetes and obesity to cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. Each was approved for a named condition after human trials, and each carries a label that states its dose, how that dose is increased and its known side effects.

The count and the disease list come from the review "Trends in peptide drug discovery" (Muttenthaler et al., 2021). Insulin was isolated in 1921 and sold as the first commercial peptide drug in 1923. Bruce Merrifield's solid-phase synthesis, published in 1963, made it practical to build a peptide one amino acid at a time, and 33 non-insulin peptide drugs were approved worldwide between 2000 and the 2022 review.

Approved peptide drugs include GLP-1 receptor agonists such as liraglutide (Victoza), dulaglutide (Trulicity) and semaglutide (Ozempic, Wegovy, Rybelsus); leuprolide, a GnRH analog used in prostate cancer and endometriosis; octreotide, a mimic of the hormone somatostatin used against growth-hormone-producing tumors; exenatide, first found in Gila monster venom; and ziconotide, from cone-snail venom, approved in 2004 for severe chronic pain. In the 2022 review's ranking, the three best-selling peptide drugs of 2019 were all GLP-1 analogs for type 2 diabetes. That family, along with the dual and triple agonists built on it, is covered compound by compound in weight loss & metabolic peptides on this site.

What are research peptides, and how do they differ from approved peptide drugs?

Research peptides are unapproved peptides, such as BPC-157, TB-500 and MOTS-c, sold online as research-use-only (RUO) chemicals, a label meaning they are not sold for human use and have not been reviewed as medicines. As of September 2026, none is FDA-approved for any use or on the 503A bulks list, the list a substance must be on before US pharmacies may compound it, although an FDA advisory committee recommended 6 of 7 candidates for that list in July 2026.

That trade is the grey market, which this site describes as the lawful sale of research chemicals with nobody upstream answerable for a given batch, and the reference page on the grey market for peptides sets out how that market works.

FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," current as of April 22, 2026, shows where these compounds stand. Four peptides remain in its Category 2 of substances that may present significant safety risks: GHRP-2, GHRP-6 and ipamorelin acetate for outsourcing facilities (the 503B route), and kisspeptin-10 for pharmacies (the 503A route). Seventeen substances, including BPC-157, TB-500 and MOTS-c, sit in its table of nominations withdrawn by their nominators. Leaving Category 2 is not permission to compound; a substance must first be added to the 503A bulks list.

The next step was an advisory review. The July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee considered seven peptides, each for specific medical uses. The committee recommended six, BPC-157, KPV, TB-500, MOTS-c, Semax and epithalon (epitalon in FDA documents), and rejected DSIP (emideltide), as the National Community Pharmacists Association reported in "FDA advisory committee nominates six peptides for pharmacies to compound." HHS must still formally approve any addition to the list. As of September 2026, BPC-157 is not on the 503A bulks list; an FDA advisory committee recommended it in July 2026, and the recommendation is not binding.

How strong is the human evidence for the peptides sold online?

The human evidence behind most peptides sold online is thin. The 2025 systematic review of BPC-157 kept 36 of the studies it screened: 35 in animals or cells, and one retrospective report in which 7 of 12 patients with knee pain said their symptoms eased for more than 6 months after an injection. Approved peptide drugs sit at the other end: one of the weight-loss trials in Wegovy's label enrolled 1,961 adults and compared the drug with a placebo.

Between those two ends sits a middle rung, human data on hormone levels with no health outcome behind them, and CJC-1295 with DAC is the clearest case of it. In two randomized, placebo-controlled, dose-escalation trials in healthy adults aged 21 to 61, reported in "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" (Teichman et al., 2006), a single injection raised growth hormone 2- to 10-fold for 6 days or more. It raised IGF-1 (insulin-like growth factor 1, a growth factor that rises when growth hormone does) 1.5- to 3-fold for 9 to 11 days. That is pharmacodynamic evidence, proof that the molecule moves a hormone, not evidence that it changes muscle, fat, recovery or health. The compound is grouped with the other growth hormone peptides in the site's library.

BPC-157's record sits lower still. Every benefit in the 2025 review comes from animal and cell studies, mostly rat models of tendon, ligament, muscle and bone injury. The one human report had no control group and described unspecified knee pain, and the review found no study of BPC-157's safety in people. Its one registered Phase 1 trial has had an unknown status since 2016. BPC-157 sits with TB-500 and the other injury-repair compounds in tissue repair & healing peptides, and its evidence maturity is preclinical-only.

The table sets the rungs side by side, and the limitation column is the one to read first.

Why are most peptides injected rather than swallowed?

Most peptides are injected because the digestive tract breaks them down before they reach the blood. The Wegovy label puts semaglutide's absolute bioavailability, the share of a dose that reaches the bloodstream, at 89% after an injection under the skin (subcutaneous) and about 1–2% from a tablet. That gap is why the tablet's maintenance dose is 25 mg a day, against 2.4 mg a week by injection.

The prescribing information, WEGOVY (semaglutide) injection, for subcutaneous use, revised in June 2026, also covers the once-daily Wegovy tablet approved in December 2025. The tablet reaches even that 1–2% only because it is formulated with an absorption enhancer, salcaprozate sodium (SNAC), and taken on an empty stomach with a small amount of water.

Peptides have two built-in weaknesses, according to the 2022 review of the field. They cross cell membranes poorly, and enzymes cut their peptide bonds quickly, which gives natural peptides short half-lives (the time the body takes to clear half a dose).

Semaglutide shows how drug makers work around both. Its label describes a GLP-1 analog that shares 94% of its sequence with the human hormone, is modified at one position to resist the enzyme DPP-4, and carries a fatty-acid side chain that binds it to albumin, the most abundant protein in blood. More than 99% of the drug circulates bound to albumin, its half-life is about a week, and that binding is what makes a once-weekly schedule possible.

Research peptides come with no such data. The 2025 review found BPC-157's pharmacokinetics (how a drug is absorbed, spread and cleared) measured only in animals, with a half-life under 30 minutes after intramuscular or intravenous doses, so no published human figure supports claims that a BPC-157 capsule reaches the blood.

How are peptide doses established, and why do most research peptides have none?

Peptide doses are established by an approved label or a published human trial, and most research peptides have neither. Wegovy's label starts semaglutide at 0.25 mg once weekly and raises it every 4 weeks to a 2.4 mg maintenance dose. CJC-1295 with DAC has doses tested in trials but no label. BPC-157 has no established human dose: the 250–500 mcg daily figures on forums are community-reported, and no trial has tested any dose.

Those are the only three forms a dose figure takes on this site: the approved label, a published trial, or "no established human dose" with the community figure reported and tagged. The table shows one example of each form.

The label rows describe an approved product taken under a prescriber. A research vial sold under the same name is a different product, and its content is unverified until someone tests it. No controlled human trial has established a cycling schedule, weeks on and weeks off, for any research peptide; the on-off patterns in forum posts are convention, not evidence.

The site's article Sorting Peptides by Dosing Evidence groups compounds by which of the three forms applies to each. For the arithmetic, the BPC-157 calculator converts a milligram figure you already have into syringe units after reconstitution, the step of dissolving the freeze-dried powder in sterile or bacteriostatic water (sterile water with 0.9% benzyl alcohol). It does not turn that figure into a tested dose.

How do you know what is actually in a peptide vial?

What is in a peptide vial is confirmed by three separate lab measurements: purity (what share of the peptide content is the main compound), identity (whether that compound is the molecule on the label) and net content (how many milligrams the vial actually holds). On this site, 7.24% of the 12,513 certificates that report a measured amount came in below 95% of the label, while 0.27% of the 13,148 purity results fell below 95% purity (verified September 2026).

Purity is measured by HPLC (high-performance liquid chromatography), which separates a sample into its components and reports the main peak's share. Identity is confirmed by mass spectrometry, which weighs the molecule and checks that its mass matches the compound named on the label. Net content is a separate quantity measurement, reported in milligrams against the label claim.

The Purity Index reports both failure rates above from the certificates published on this site, and it deliberately reports no wrong-molecule rate, because mass-spectrometry identity results are not recorded in a form it can count (verified September 2026). Underdosing is the common failure and impurity the rare one. A vial can pass on purity and fail on identity, the gap explained in Why a Peptide Can Be 99 Percent Pure and Still Be Entirely the Wrong Molecule, which is worth reading before trusting any certificate.

The platform lists 13,190 published certificates, and 11,458 of them feed the Purity Index, whose composite stands at 99.51 across 64 compounds and 26 labs (verified September 2026). BPC-157 alone has 877 published certificates, and its 660 purity results give it an index of 99.38 (verified September 2026). The index describes itself as a picture of the samples that were tested and submitted, not of the market as a whole, and it notes that a vendor's own certificate reports a batch the vendor selected and paid to test.

If you already hold a vial, how to test your peptides explains how to send a sample to a third-party lab and what to ask it to measure. Before relying on a seller's certificate, the peptide shops directory shows the lab tests each listed shop has on file.

What are the side effects and risks of peptides?

Peptide side effects depend on the molecule and on what is actually in the vial. For an approved drug they are measured: the Wegovy label reports nausea in 44% of adults on the 2.4 mg weekly dose against 16% on placebo, and warns about pancreatitis and gallbladder disease. For most research peptides nobody has measured them, and the 2025 review of BPC-157 found no study of its safety in people.

The same label carries a boxed warning, its strongest kind, because semaglutide caused thyroid C-cell tumors in rodents. It rules the drug out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 (multiple endocrine neoplasia type 2, an inherited tumor syndrome), and it reports gallstones in 1.6% of adults on the injection against 0.7% on placebo. Low blood sugar becomes a risk when semaglutide is combined with insulin or a sulfonylurea.

For research peptides, the risks FDA has named concern the material as much as the molecule. FDA's Category 2 page flags a possible immune reaction to aggregated peptide or to peptide-related impurities for many of the compounds it lists. It records possible effects on cortisol and blood sugar for GHRP-6, and it cites published case reports of melanoma after Melanotan II. The site's guide to Peptide Side Effects sorts the documented effects by compound class, route and the tier of evidence behind each.

Stop and seek care: swelling of the face or throat, difficulty breathing or hives after an injection are signs of a serious allergic reaction; spreading redness, warmth or pus at an injection site with fever is an infection; severe or persistent abdominal pain with vomiting on a GLP-1 drug can be pancreatitis; confusion, sweating or shaking on an IGF-1 or insulin-adjacent compound can be hypoglycaemia. Call your local emergency number (911 in the US, 112 in the EU, 999 in the UK, 000 in Australia) or go to an emergency department, and bring the vial and its label. Research-use vials are not approved products in any jurisdiction, even where a prescription product of the same molecule exists; no article on this site replaces a clinician who knows your history.

What comes next for peptide drugs?

The next peptide drugs are arriving as pills and as single molecules that act on several receptors at once. Semaglutide became a once-daily 25 mg Wegovy tablet in December 2025, and retatrutide, one peptide that activates the GLP-1, GIP and glucagon receptors, has the Phase 3 data its maker says an obesity filing needs but is not approved. Eli Lilly plans to file for US approval in the first quarter of 2027.

Eli Lilly's results release "Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress" (August 5, 2026) calls the retatrutide clinical data package complete and sets the US filing for the first quarter of 2027. GIP (glucose-dependent insulinotropic polypeptide) and glucagon are two more hormones, so retatrutide copies the signals of three natural hormones with one molecule. Demand runs ahead of approval: retatrutide is the most-tested compound on this site, with 1,318 published certificates (verified September 2026).

Behind those two sit more than 170 peptides in active clinical development, the count in the 2022 review, and the chemistry behind them keeps attacking the same two weaknesses. Cyclizing or stapling a peptide, bracing it into a ring or a rigid helix, helps it resist enzymes, and attaching a fatty acid or a polymer keeps it in the blood longer.

For the six research peptides the advisory committee backed, the next step is regulatory rather than scientific: an addition to the 503A bulks list needs HHS's formal approval, and none had been made as of September 2026. Whatever reaches the market next, the check for a vial you already hold stays the same: ask for the mass-spectrometry result as well as the purity figure, and match the batch number on the certificate to the one on the vial.

Frequently Asked Questions

Are peptides steroids?

No. Peptides are chains of amino acids, while anabolic steroids are synthetic versions of hormones such as testosterone, a different chemical class regulated under different rules. The site's comparison Peptides vs SARMs vs Steroids sets their legal categories side by side.

Can a peptide work if you swallow it?

Only with engineering, and even then barely: the Wegovy label puts the absolute bioavailability of oral semaglutide at about 1–2%, and the tablet needs an absorption enhancer to reach that. No human absorption figure has been published for research peptides sold as capsules, and BPC-157's pharmacokinetic data come from animals only.

Is it legal to buy research peptides in the US?

In the US, research peptides are sold as research chemicals, and the 2025 BPC-157 review notes that BPC-157 products are sold legally under that label and that possessing BPC-157 is not illegal, because it is not a DEA-scheduled substance. None of the peptides discussed here is approved for human use, and none may be compounded by a US pharmacy as of September 2026. Athletes should check the current WADA Prohibited List before using any peptide.

When should you talk to a clinician before using a peptide?

Talk to a clinician before any peptide if you have a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, diabetes treated with insulin or a sulfonylurea, or a pregnancy. The Wegovy label contraindicates the first, warns about pancreatitis and about low blood sugar with those diabetes drugs, and says to stop the drug when a pregnancy is recognized. For a research peptide, any unexplained reaction is a reason to stop and get checked, because BPC-157 and many others have no published human safety studies.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use; research peptides are sold for laboratory use and are not manufactured, tested or labelled to pharmaceutical standards. Peptigrity does not recommend doses: every dose figure above is an approved-label value, a published-trial value or a community report, and is labelled as such — a community report is not a recommendation. Self-injection carries risks of infection, allergic reaction and dosing error; signs of a serious allergic reaction, an injection-site infection with fever, severe abdominal pain, or confusion and sweating on an IGF-1 or insulin-adjacent compound are medical emergencies — call your local emergency number. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.